

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.047C1	APPLICATION NO. 09/619,059
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT DeYoung, et al.	
		FILING DATE July 18, 2000	GROUP <u>1614</u> <u>1631</u>

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>MPA</i>	1	5,082,774	1/92	Heinrich			
	2	5,210,185	5/93	Della Valle et al.			
	3	5,457,034	10/95	Della Valle et al.			
	4	5,763,394	6/98	O'Connor et al.			

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
MPA	5	WO 94/26302	11/24/94	WIPO				
↓	6	WO 95/05845	03/02/95	WIPO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
<i>MPA</i>	7	Apfel et al. (1991) Nerve growth factor prevents toxic neuropathy in mice. Ann.Neurol. 29(1):87-90.
	8	Apfel et al. (1992) Nerve growth factor prevents experimental cisplatin neuropathy. Ann. Neurol. 31:76-80.
	9	Bothwell et al. (1977) Dissociation equilibrium constant of $\beta$ nerve growth factor. The Journal of Biological Chemistry. 252(23):8532-8536.
	10	Canova-Davis et al. Amino-terminal serine to glycine post-translational modification observed in nerve growth factor biosynthesized in Chinese hamster ovary cells. Analytical Methods. pp.230-231.
	11	Q&A biochem (1994/1995) Product Catalog. p.233.
	12	De Young et al. (1994) Temperature and PH dependence of recombinant human nerve growth factor dimer dissociation. Biophys.Journal 66(2):A401.
	13	Greene (1977) A quantitative bioassay for nerve growth factor (NGF) activity employing a clonal pheochromocytoma cell line. Brain research. 133:350-353.
	14	McDonald et al. (1991) New protein fold revealed by a 2.3-A resolution crystal structure of nerve growth factor. Nature. 354:411-414.
	15	Moore et al. (1975) The use of hybrid molecules in a study of the equilibrium between nerve growth factor monomers and dimers. Neurobiology. 5:369-381.
	16	Petty et al. (1994) The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann. Neurol. 36:244-246.
	17	Reed et al. (1987) Lysis of human red blood cells in the presence of various cosolvents. III. The relationship between hemolytic potential and structure. Journal of Parenteral Science & Technology. 41(1):37-39.
	18	(1990) Remington's Pharmaceutical Sciences. 18th Edition, Mack Publishing Co., Easton, PA. pp.1056,1286,1449.
	19	Schmelzer et al. (1992) Biochemical characterization of recombinant human nerve growth factor. Journal of Neurochemistry. 59(5):1675-1683.
	20	Thoenen et al. (1980) Physiology of nerve growth factor. Physiological Reviews. 60(4):1284-1335.
	21	Timm et al. (1992) Equilibrium denaturation studies of mouse $\beta$ -nerve growth factor. Protein Science. 1:236-244.
	22	Timm et al. (1994) Comparative equilibrium denaturation studies of the neurotrophins: nerve growth factor, brain-derived neurotrophic factor, neurotrophin 3, and neurotrophin 4/5. Biochemistry. 33:4667-4676.

S:\DOCS\JMJ\JMJ-4894.DOC\102300

EXAMINER <i>MP Allen</i>	DATE CONSIDERED <i>9/27/01</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	